Improved treatments for chronic myeloid leukaemia have dramatically increased survival

December 12, 2012
Improved treatments for chronic myeloid leukaemia have dramatically increased survival

Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 per cent in the late 1990s, according to a new report from the National Cancer Intelligence Network (NCIN), published today.

The improvements are largely down to a family of drugs called (TKIs) which have now become the standard treatment for the disease. The first of these was imatinib (), which was licensed in 2001.

The Northern and Yorkshire Cancer Registry and Information Service (NYCRIS), on behalf of the NCIN Haematology Site Specific Clinical Reference Group (SSCRG), looked at the rates of people in England getting, dying from and surviving a range of different between 1995 and 2008. And it is the first national study in England to look at survival for different types of leukaemia.

For patients diagnosed with CML, researchers found that the chance of surviving the disease for at least five years after diagnosis rose from 41 per cent to 57 per cent in men and from 38 per cent to 59 per cent in women between the late 1990s and the early 2000s.

CML is a relatively rare form of leukaemia that mostly affects older people, with around 700 cases diagnosed in the UK every year.

Dr Robin Ireland, chair of the SSCRG at the NCIN, said: "It's really exciting to see the enormous difference can make in treating cancer. And, as this new data shows, TKI's can be considered a revolutionary treatment for Chronic Myeloid Leukaemia.  

"Basic research has given us a greater biological understanding of , which has led to the development of successful targeted that are now the first line treatment for CML. TKIs target cancer cells by blocking the molecules they make, which stops them from multiplying. These drugs have completely changed the outlook for patients with this disease and it's the first example of our improved understanding of cell molecular biology leading to the design of a specific inhibitor of the disease."

Dr Steven Oliver, Haematological Cancer Epidemiology Lead at NYCRIS and lead author of the report, said: "This report shows that, although the number of people developing Chronic hasn't changed much since 2001, survival from the disease has greatly improved.

"What's even more promising is that, in the last four years, second and third generations of these drugs have been developed. We believe more and more CML patients have been receiving TKI's and we'd predict that the improvements in survival should be even greater in the future."

Chris Carrigan, head of the National Cancer Intelligence Network (NCIN), said: "Being able to link data on the diagnosis, treatment and outcomes for cancer patients allows us to identify where improved care is having an effect on peoples lives. The improvements in survival demonstrated here highlight the difference that effective treatments can make."

Explore further: Scientists discover how to beat resistance to standard leukaemia drug

Related Stories

Scientists discover how to beat resistance to standard leukaemia drug

December 9, 2011
(Medical Xpress) -- Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according ...

Nearly 10 per cent of bowel cancer patients die within a month of diagnosis

March 27, 2012
(Medical Xpress) -- Almost 10 per cent of bowel cancer patients die within a month of being diagnosed according to new analysis by the National Cancer Intelligence Network (NCIN), published today.

Screening helps early diagnosis of bowel cancer

June 18, 2012
(Medical Xpress) -- Patients who attend bowel screening are more likely to be diagnosed with bowel cancer at an early stage - when there is a better chance of survival - than those who wait until they have symptoms of the ...

Death rates from ovarian cancer have fallen by 20 per cent over last decade

November 20, 2012
The rates of women dying from ovarian cancer in England have fallen from 11.2 women in every 100,000 (3,820 cases) in 2001 to 8.8 per 100,000 (3,453 cases) in 2010 – a drop of around 20 per cent, according to a new report ...

For elderly patients, nearly 1 in 3 cancer diagnoses result from ER admissions

September 24, 2012
Almost a third (31 per cent) of cancers in the over 70s – around 38,300 a year in England – are diagnosed through emergency admission to hospital, according to new research by the National Cancer Intelligence Network ...

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012
(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.